Lagerstandorte

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

Binimetinib Acid Nitroso Impurity

● Auf Lager

Katalog-Nr.::	VE0025866
CAS-Nr.::	N/A
Summenformel::	C15H9BrF2N4O3
Molare Masse::	411.16 g/mol

Angebot anfordern

Zur RFQ-Liste hinzufügen

Zusätzliche Informationen zu

Parent drug

Binimetinib

IUPAC-Name

5-((4-bromo-2-fluorophenyl)(nitroso)amino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylic acid

Pharmacopeial Synonyms

N/A

Synonyme

N/A

SMILES

OC(C1=C(N(N=O)C2=CC=C(Br)C=C2F)C(F)=C3C(N(C)C=N3)=C1)=O

InChI

InChI=1S/C15H9BrF2N4O3/c1-21-6-19-13-11(21)5-8(15(23)24)14(12(13)18)22(20-25)10-3-2-7(16)4-9(10)17/h2-6H,1H3,(H,23,24)

Beschreibung

Binimetinib acid nitroso impurity is a nitroso-derived process and degradation-related impurity of concern in binimetinib drug substance manufacturing, formed via inadvertent nitrosation of the acid functionality under oxidative or nitrosating conditions. It requires rigorous impurity profiling and control because nitroso species can affect safety and stability profiles. Identification and quantification are routinely performed by HPLC with UV detection and confirmed by LC-MS, high resolution MS and NMR, with isolation by preparative HPLC for reference standard generation. Risk mitigation focuses on controlling nitrosating reagents, pH, solvent quality and process temperatures, implementing purge studies and stability testing to meet regulatory qualification thresholds.